All these results suggest that the antioxidative effect of PGRN may depend on the NFE2L2/ARE signaling pathway activity and inhibiting NFE2L2 expression can suppress the antioxidative activity of PGRN in cervical cancer. The gene discussed is NFE2L2; the disease is cervical carcinoma.